Aman Chauhan
University of Kentucky
CancerInternal medicineRadiologySurgeryPathologyOncologyPediatricsAdverse effectSomatostatinChemotherapyImmunotherapyNeuroendocrine tumorsDiseaseMEDLINEEverolimusRegimenIncidence (epidemiology)Cancer researchClinical trialMedicineGastroenterology
114Publications
13H-index
390Citations
Publications 106
Newest
#1Aasems Jacob (UK: University of Kentucky)H-Index: 4
#2Gaby Gabriel (UK: University of Kentucky)H-Index: 3
Last. Aman Chauhan (UK: University of Kentucky)H-Index: 13
view all 6 authors...
Source
#1Virginia Corbett (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 1
#2Susanne M. Arnold (UK: University of Kentucky)H-Index: 24
Last. Aman Chauhan (UK: University of Kentucky)H-Index: 13
view all 4 authors...
Background: Large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive cancer with a dismal prognosis. The majority of cases occur in the lung and the gastrointestinal tract; however, it can occur throughout the body. Recently advances in the understanding of the molecular underpinnings of this disease have paved the way for additional novel promising therapies. This review will discuss the current best evidence for management of LCNEC and new directions in the classification and treatmen...
Source
#1Robert A Ramirez (VUMC: Vanderbilt University Medical Center)
#2Katharine Thomas (LSU Health Sciences Center New Orleans)
Last. Aman ChauhanH-Index: 13
view all 0 authors...
Source
#1Aman ChauhanH-Index: 13
#2Alexandre PrieurH-Index: 8
Last. Dominique JoubertH-Index: 29
view all 11 authors...
Source
#1Aman ChauhanH-Index: 13
#2Charles A. KunosH-Index: 24
Last. Elise C. KohnH-Index: 78
view all 11 authors...
Source
Source
Source
#1Aman Chauhan (UK: University of Kentucky)H-Index: 13
#2Satya Das (VUMC: Vanderbilt University Medical Center)H-Index: 9
Last. Lowell Anthony (UK: University of Kentucky)H-Index: 29
view all 10 authors...
BACKGROUND Neuroendocrine tumors, although relatively rare in incidence, are now the second most prevalent gastrointestinal neoplasm owing to indolent disease biology. A small but significant sub-group of neuroendocrine tumor patients suffer from diarrhea. This is usually secondary to carcinoid syndrome but can also be a result of short gut syndrome, bile acid excess or iatrogenic etiologies. Recently, an amino acid based oral rehydration solution (enterade® Advanced Oncology Formula) was found ...
Source
Source
#1Zeta ChowH-Index: 1
#2Jeremy Johnson (UK: University of Kentucky)H-Index: 2
Last. Piotr G. RychahouH-Index: 37
view all 13 authors...
Patients with advanced-stage gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have a poor overall prognosis despite chemotherapy and radiotherapy (e.g., peptide receptor radionuclide therapy (PRRT)). Better treatment options are needed to improve disease regression and patient survival. The purpose of this study was to examine a new treatment strategy by combining PI3K/mTOR dual inhibition and radiotherapy. First, we assessed the efficacy of two PI3K/mTOR dual inhibitors, PF-04691502 and ...
Source